{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:55:14Z","timestamp":1790664914249,"version":"4.1.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.clml.2021.07.012","type":"journal-article","created":{"date-parts":[[2021,7,18]],"date-time":"2021-07-18T17:33:17Z","timestamp":1626629597000},"page":"805-811","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["SOHO State of the Art Updates and Next Questions: The Past, Present and Future of Venetoclax-Based Therapies in AML"],"prefix":"10.1016","volume":"21","author":[{"given":"Anagha","family":"Inguva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Pollyea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.07.012_bib0001","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.22779","article-title":"Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes","volume":"110","author":"Knipp","year":"2007","journal-title":"Cancer."},{"key":"10.1016\/j.clml.2021.07.012_bib0002","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.clml.2021.07.012_bib0003","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1182\/blood-2010-03-276485","article-title":"Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Blood."},{"key":"10.1016\/j.clml.2021.07.012_bib0004","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1182\/bloodadvances.2017015222","article-title":"Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission","volume":"2","author":"Vasu","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.clml.2021.07.012_bib0005","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.clml.2021.07.012_bib0006","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.clml.2021.07.012_bib0007","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat Med."},{"key":"10.1016\/j.clml.2021.07.012_bib0008","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719882822","article-title":"Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy","volume":"10","author":"Richard-Carpentier","year":"2019","journal-title":"Ther Adv Hematol."},{"key":"10.1016\/j.clml.2021.07.012_bib0009","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clml.2021.07.012_bib0010","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.26039","article-title":"Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study","volume":"96","author":"Pollyea","year":"2021","journal-title":"Am J Hematol."},{"key":"10.1016\/j.clml.2021.07.012_bib0011","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med."},{"key":"10.1016\/j.clml.2021.07.012_bib0012","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1080\/10428194.2020.1861278","article-title":"Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax","volume":"62","author":"Marques-Piubelli","year":"2021","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.clml.2021.07.012_bib0013","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26207","article-title":"Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14)","author":"Nahi","year":"2021","journal-title":"Am J Hematol."},{"key":"10.1016\/j.clml.2021.07.012_bib0014","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-20-1465","article-title":"Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.","author":"Pullarkat","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.clml.2021.07.012_bib0015","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.ccell.2020.10.010","article-title":"Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia","volume":"38","author":"Bhatt","year":"2020","journal-title":"Cancer Cell."},{"key":"10.1016\/j.clml.2021.07.012_bib0016","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1158\/2159-8290.CD-17-0797","article-title":"Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax","volume":"7","author":"Leverson","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.clml.2021.07.012_bib0017","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/bloodadvances.2019000937","article-title":"Venetoclax for AML: changing the treatment paradigm","volume":"3","author":"Pollyea","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.clml.2021.07.012_bib0018","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ccr.2006.03.027","article-title":"Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members","volume":"9","author":"Certo","year":"2006","journal-title":"Cancer Cell."},{"key":"10.1016\/j.clml.2021.07.012_bib0019","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/978-1-4939-8861-7_4","article-title":"BH3 Profiling: A Functional Assay to Measure Apoptotic Priming and Dependencies","volume":"1877","author":"Fraser","year":"2019","journal-title":"Methods Mol Biol."},{"key":"10.1016\/j.clml.2021.07.012_bib0020","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-19-1900","article-title":"5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis","volume":"26","author":"Jin","year":"2020","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.clml.2021.07.012_bib0021","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.clml.2021.07.012_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2021.101251","article-title":"Mechanisms for resistance in AML insights into molecular pathways mediating resistance to venetoclax","volume":"34","author":"Konopleva","year":"2021","journal-title":"Best Pract Res Clin Haematol."},{"key":"10.1016\/j.clml.2021.07.012_bib0023","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1182\/bloodadvances.2019000243","article-title":"Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia","volume":"3","author":"Winters","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.clml.2021.07.012_bib0024","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1182\/blood.V81.11.3091.3091","article-title":"High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy","volume":"81","author":"Campos","year":"1993","journal-title":"Blood."},{"key":"10.1016\/j.clml.2021.07.012_bib0025","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/10245330400020454","article-title":"Apoptosis and immaturity in acute myeloid leukemia","volume":"10","author":"Del Principe","year":"2005","journal-title":"Hematology."},{"key":"10.1016\/j.clml.2021.07.012_bib0026","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.clml.2021.07.012_bib0027","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.ccell.2018.10.005","article-title":"Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells","volume":"34","author":"Jones","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2021.07.012_bib0028","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nature22993","article-title":"Tracing the origins of relapse in acute myeloid leukaemia to stem cells","volume":"547","author":"Shlush","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.clml.2021.07.012_bib0029","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/2159-8290.CD-19-0117","article-title":"Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment","volume":"9","author":"Chen","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2021.07.012_bib0030","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.cmet.2019.01.011","article-title":"Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity","volume":"29","author":"Lin","year":"2019","journal-title":"Cell Metab"},{"key":"10.1016\/j.clml.2021.07.012_bib0031","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1038\/leu.2008.206","article-title":"Investigating human leukemogenesis: from cell lines to in vivo models of human leukemia","volume":"22","author":"Kennedy","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.07.012_bib0032","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1266\/ggs.83.339","article-title":"A comparison of gene expression profiles between primary human AML cells and AML cell line","volume":"83","author":"Lee","year":"2008","journal-title":"Genes Genet Syst"},{"key":"10.1016\/j.clml.2021.07.012_bib0033","doi-asserted-by":"crossref","first-page":"14040","DOI":"10.1002\/jcp.28091","article-title":"The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML","volume":"234","author":"Nguyen","year":"2019","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.clml.2021.07.012_bib0034","article-title":"Venetoclax enhances T cell-mediated anti-leukemic activity by increasing ROS production","author":"Lee","year":"2021","journal-title":"Blood."},{"key":"10.1016\/j.clml.2021.07.012_bib0035","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-021-01076-4","article-title":"Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine","volume":"14","author":"Buettner","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2021.07.012_bib0036","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.beha.2019.05.008","article-title":"Venetoclax-based therapies for acute myeloid leukemia","volume":"32","author":"Guerra","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.clml.2021.07.012_bib0037","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.012_bib0038","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2021.07.012_bib0039","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","article-title":"Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group","volume":"33","author":"Bennett","year":"1976","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.07.012_bib0040","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3324\/haematol.2018.214882","article-title":"Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia","volume":"105","author":"Kuusanm\u00e4ki","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.07.012_bib0041","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.012_bib0042","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1182\/bloodadvances.2019001267","article-title":"Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens","volume":"4","author":"Lachowiez","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.07.012_bib0043","doi-asserted-by":"crossref","first-page":"E154","DOI":"10.1002\/ajh.26122","article-title":"Decitabine and venetoclax for IDH1\/2-mutated acute myeloid leukemia","volume":"96","author":"Venugopal","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.07.012_bib0044","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/bloodadvances.2020004173","article-title":"Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax","volume":"5","author":"Lachowiez","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.07.012_bib0045","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/s43018-020-00126-z","article-title":"Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells","volume":"1","author":"Stevens","year":"2020","journal-title":"Nat Cancer"},{"key":"10.1016\/j.clml.2021.07.012_bib0046","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2020010167","article-title":"Intact TP53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias","author":"Thijssen","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.012_bib0047","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2020-140182","article-title":"Outcomes of TP53-Mutant Acute Myeloid Leukemia with Venetoclax and Decitabine","volume":"136","author":"Kim","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.012_bib0048","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/ajh.26186","article-title":"Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases","volume":"96","author":"Gangat","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.07.012_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106456","article-title":"Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm","volume":"98","author":"Tremblay","year":"2020","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2021.07.012_bib0050","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1182\/blood-2018-03-828269","article-title":"BCL-2 inhibition in AML: an unexpected bonus?","volume":"132","author":"Konopleva","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.012_bib0051","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41419-019-1801-0","article-title":"Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling","volume":"10","author":"Seyfried","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.clml.2021.07.012_bib0052","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1182\/blood-2012-02-414060","article-title":"Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia","volume":"120","author":"Davids","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.012_bib0053","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138377","article-title":"Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating Drugs","volume":"10","author":"Ishizawa","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2021.07.012_bib0054","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s43018-020-0103-x","article-title":"Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia","volume":"1","author":"Zhang","year":"2020","journal-title":"Nat Cancer"},{"key":"10.1016\/j.clml.2021.07.012_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100672","article-title":"Targeting MCL-1 in hematologic malignancies: Rationale and progress","volume":"44","author":"Wei","year":"2020","journal-title":"Blood Rev"},{"key":"10.1016\/j.clml.2021.07.012_bib0056","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","article-title":"A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia","volume":"8","author":"Ramsey","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2021.07.012_bib0057","first-page":"27696","article-title":"Targeting MCL-1\/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in","volume":"6","author":"Lin","year":"2016","journal-title":"Acute Myeloid Leukemia. Sci Rep."},{"key":"10.1016\/j.clml.2021.07.012_bib0058","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3324\/haematol.2018.205534","article-title":"Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models","volume":"105","author":"Han","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.07.012_bib0059","doi-asserted-by":"crossref","first-page":"6099","DOI":"10.1111\/jcmm.13886","article-title":"Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1","volume":"22","author":"Luedtke","year":"2018","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.clml.2021.07.012_bib0060","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2020-136872","article-title":"Acquired Mutations in BAX Confer Resistance to BH3 Mimetics in Acute Myeloid Leukemia","volume":"136","author":"Moujalled","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.012_bib0061","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2021.07.012_bib0062","first-page":"11","article-title":"Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response","author":"Sharon","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clml.2021.07.012_bib0063","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.stem.2020.07.021","article-title":"Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells","volume":"27","author":"Jones","year":"2020","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.clml.2021.07.012_bib0064","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","article-title":"10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial","volume":"7","author":"DiNardo","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2021.07.012_bib0065","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/bloodadvances.2020003734","article-title":"Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/refractory AML","volume":"5","author":"Stahl","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.07.012_bib0066","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ajh.25000","article-title":"Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","volume":"93","author":"DiNardo","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.07.012_bib0067","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.3324\/haematol.2018.188094","article-title":"Efficacy of the combination of venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia","volume":"103","author":"Aldoss","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.07.012_bib0068","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00277-019-03719-6","article-title":"Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study","volume":"98","author":"Ram","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2021.07.012_bib0069","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.649209","article-title":"Outcomes of Adults With Relapsed\/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center","volume":"11","author":"Tenold","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2021.07.012_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106314","article-title":"Venetoclax combination therapy in relapsed\/refractory acute myeloid leukemia: A single institution experience","volume":"90","author":"Gaut","year":"2020","journal-title":"Leuk Res"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021002834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021002834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:37:51Z","timestamp":1761871071000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021002834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":70,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S2152265021002834"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.07.012","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions: The Past, Present and Future of Venetoclax-Based Therapies in AML","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}